October 15, 2018
1 min read

Autograft bone yielded better rates of osseous integration with all-polyethylene glenoid

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

CHICAGO — Results presented at the American Shoulder and Elbow Surgeons Annual Meeting showed no difference in functional outcome scores and revision rates between different surgical techniques in total shoulder arthroplasty treated with an all-polyethylene glenoid designed for bone ingrowth. However, autograft bone had greater rates of osseous integration.

Evan Lederman
Evan S. Lederman

Evan S. Lederman, MD, and colleagues randomly assigned 153 patients undergoing primary total shoulder arthroplasty performed with a press-fit humeral stem and a peripherally cemented pegged glenoid designed for central bone ingrowth to be treated with either no graft, an autogenous bone graft or a demineralized bone matrix. Researchers assessed functional outcome, osseous integration of the central peg and glenoid loosening at a minimum of 1 year postoperatively.

In his presentation, Lederman noted no differences in range of motion or patient-outcome scores between the groups. He added osseous integration occurred in 90% of the autograft group, in 62% of the no graft group and in 70% of the demineralized bone matrix group.

“There was statistical significance between the no graft and the autograft group, and between the [demineralized bone matrix] DBM and the autograft group, and there was no difference between the DBM and autograft group,” Lederman said.

Lederman noted no association between osseous integration and functional outcome scores and range of motion. – by Casey Tingle



Denard PJ, et al. Paper 19. Presented at: American Shoulder and Elbow Surgeons Annual Meeting; Oct. 12-14, 2018; Chicago.


Disclosure: Lederman reports he receives IP royalties, is a paid consultant, paid presenter or speaker for and receives research support from Arthrex Inc.